A Phase 3, Randomized, Observer-blind, Controlled Trial to Assess the Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
Latest Information Update: 18 Aug 2021
Price :
$35 *
At a glance
- Drugs Coronavirus vaccine-Wuhan Institute of Biological Products (Primary) ; Influenza virus vaccines (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Acronyms ECOVA-01
- 05 Aug 2021 New trial record